ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026
Application and effect of lactic acid probiotic bacteria in the blue crab Callinectes arcuatus under laboratory conditions.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To avoid losses by viral and bacterial diseases in organisms of aquaculture importance is the use of probiotics. Lactic acid bacteria have shown to improve growth and immune response in crustaceans. The present work aimed to isolate, biochemically and molecularly characterize free and microencapsulated LAB strains (ion gelation) and evaluate the effect on growth, survival and immune system of the blue crab C. arcuatus. A total of 45 presumptive LAB strains were isolated from the intestine of C. bellicosus. Only two of them showed gamma hemolysis (A2-2 y A2-4b), were Gram-negative, cocci, with hydrophobicity, autoaggregation and medium biofilm formation and had a 99% similarity to Pediococcus pentosaceus. The strains were microencapsulated with a viability of 42.6% (A2-2) and 5.8% (A2-4b) for 90 days of shelf life. In the in vitro release, it was observed that the highest percentage occurred in the intestine extract where LAB were microencapsulated (95.00 ± 0.45%) and as for the effect of microcapsules of P. pentosaceus (A2-2 and A2-4b) added in the diet, it was observed that in the SGR, T V presented the highest daily growth compared to the control (without microcapsules) and other treatments (P < 0.05); the highest survival was presented in T V (83 ± 3.33%) (P < 0.05). In the immune response, an increase in the number of hemocytes was observed, while the values of superoxide anion, poPro and PO were minimal in the treatments with microencapsulated LAB, with a frequency of application every 2 days in the food.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.